Hemispherx Biopharma Announces Major Breakthrough:
Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic First Product Approved for ME/CFS Indication Anywhere in the World.
Ampligen Approved in Argentina – First in the World 2016-08-23